We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

46 hedge funds and large institutions have $60M invested in ProQR Therapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

278% more capital invested

Capital invested by funds: $15.9M → $60M (+$44.1M)

7% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 15

2% less funds holding

Funds holding: 47 → 46 (-1)

6.4% less ownership

Funds ownership: 29.8% → 23.4% (-6.4%)

12% less call options, than puts

Call options by funds: $655K | Put options by funds: $746K

36% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 14

Holders
46
Holders Change
-1
Holders Change %
-2.13%
% of All Funds
0.74%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
14
Increased
9
Reduced
14
Closed
15
Calls
$655K
Puts
$746K
Net Calls
-$91K
Net Calls Change
-$131K

Top Buyers

Rank Fund Capital Flow
1
MCM
M28 Capital Management
Connecticut
+$1.19M
2
IC
Ikarian Capital
Texas
+$554K
3
Marshall Wace
Marshall Wace
United Kingdom
+$455K
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$426K
5
Millennium Management
Millennium Management
New York
+$247K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$2.17M
2
PM
Prosight Management
Texas
-$1.28M
3
MAM
Monaco Asset Management
Monaco
-$1M
4
Fidelity International
Fidelity International
Bermuda
-$669K
5
BlackRock
BlackRock
New York
-$633K
Name Holding Trade Value Shares
Change 		Change in
Stake
PFM
1
Privium Fund Management
Netherlands
$18M – – –
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$13.4M +$426K +325,467 +10%
MCM
3
M28 Capital Management
Connecticut
$7.07M +$1.19M +908,800 +91%
OM
4
Opaleye Management
Massachusetts
$5.4M -$2.17M -1,655,000 -53%
Macquarie Group
5
Macquarie Group
Australia
$2.29M – – –
IC
6
Ikarian Capital
Texas
$1.56M +$554K +422,625 New
Marshall Wace
7
Marshall Wace
United Kingdom
$1.56M +$455K +347,185 +473%
Deutsche Bank
8
Deutsche Bank
Germany
$1.43M – – –
Morgan Stanley
9
Morgan Stanley
New York
$1.4M -$130K -99,063 -21%
Two Sigma Investments
10
Two Sigma Investments
New York
$1.14M -$119K -91,033 -23%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$931K +$102K +78,200 +45%
Millennium Management
12
Millennium Management
New York
$699K +$247K +188,916 New
AIC
13
AWM Investment Company
New York
$617K +$218K +166,667 New
MAM
14
Monaco Asset Management
Monaco
$611K -$1M -766,400 -82%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$610K +$216K +164,821 New
FSA
16
Franklin Street Advisors
North Carolina
$555K – – –
Bank of Montreal
17
Bank of Montreal
Ontario, Canada
$381K +$134K +102,551 New
GGHC
18
Gilder Gagnon Howe & Co
New York
$359K -$34 -26 -0%
BFM
19
Boothbay Fund Management
New York
$334K +$118K +90,285 New
CSS
20
Cubist Systematic Strategies
Connecticut
$315K +$112K +85,247 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$134K – – –
Simplex Trading
22
Simplex Trading
Illinois
$130K +$43.1K +32,922 +1,348%
Bank of America
23
Bank of America
North Carolina
$120K +$16 +12 +0%
Osaic Holdings
24
Osaic Holdings
Arizona
$85K +$655 +500 +2%
GCP
25
GSA Capital Partners
United Kingdom
$80K +$28.2K +21,514 New
1
2 3

PRQR Hedge Fund Activity: Q4 2022 in Review

46 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2022, worth a combined $60M — up 278% from $15.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of PRQR and 14 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 9 added.

The largest buyer was M28 Capital Management, adding an estimated $1.19M. The largest seller was Opaleye Management, cutting an estimated $2.17M.

  • 46 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2022, down from 47 in Q3 2022.
  • Funds reported $60M of ProQR Therapeutics stock for Q4 2022, up 278% quarter-over-quarter.
  • 14 funds opened new ProQR Therapeutics positions in Q4 2022 and 15 closed out, a net change of -1 holder.
  • The largest ProQR Therapeutics buyer in Q4 2022 was M28 Capital Management, an estimated $1.19M added.
  • The largest ProQR Therapeutics seller in Q4 2022 was Opaleye Management, an estimated $2.17M sold.

Based on aggregated 13F filings for Q4 2022.